MOY 02 Transcutaneous Fluorescence Sensing of Gastrointestinal Permeability in Humans: Cross-Cohort Validation of a Novel Fluoroscopic Device in Health, Disease, and Challenge Models
Clicks: 5
ID: 323864
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.2
/100
5 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #67 of 432 articles by views in the british journal of surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Aims Intestinal permeability is increasingly recognised as a feature of inflammatory and functional gastrointestinal disorders1,2, both of which present overlapping symptoms3 and diagnostic ambiguity4, contributing to disease burden5,6. Existing diagnostics are limited by heterogeneity and confounding from gastric motility7,8. To address these constraints, we developed Transcutaneous Fluorescence Spectroscopy (TFS), a non-invasive method that uses oral fluorescein to dynamically quantify intestinal permeability9,10. This study evaluated the discriminatory performance of TFS-derived biomarkers across functional and inflammatory disease states. Method A prospective single-centre study enrolled 66 participants: healthy controls (n=8, pre/post-indomethacin), IBS patients (n=21, pre/post low-FODMAP diet), and Crohn’s disease (CD) patients (n=36) stratified by activity. TFS measurements were collected for 180 minutes following fluorescein ingestion. Fluorescence–time curves were processed with a Savitzky-Golay filter before extracting peak intensity, time-to-peak, and the area under the fluorescence curve (AUC). A Random Forest classifier was trained on curve profiles to classify disease states. Results CD patients demonstrated higher peak intensity than both IBS (p<0.0001, r=0.68) and controls (p<0.0001, r=0.50), with IBS participants showing lower peak intensity compared to controls (p<0.0001, r=0.11). CD showed elevated AUC compared with IBS (p<0.0001, r=0.77) and controls (p-0.0078, r=0.39). IBS patients also demonstrated lower AUC compared to controls (p=0.0191, r=0.38). Classification accuracy reached 86% for CD vs IBS,80.6% for IBS vs controls, and 66% for 3-class classification. No significant pre/post-FODMAP differences were detected. Conclusions TFS demonstrates promise as a non-invasive tool for distinguishing gastrointestinal disorders. With broader multi-centre validation and longitudinal assessment, TFS may support personalised treatment approaches and facilitate non-invasive disease stratification.
| Reference Key |
openalex_W7172541362
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Pratik Ramkumar, Qian Chen, Nilanjan Mandal, Jonathan Gan, Elena Montfort-Sanchez, Alex Thompson |
| Journal | the british journal of surgery |
| Year | 2026 |
| DOI |
10.1093/bjs/znag087.002
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.